Patients With Rectal Cancer: a "Wait-and-see" Approach

Patients with histologically proven adenocarcinoma of the rectum will receive pelvic radiotherapy to a dose of 45Gy in 25 fractions with a tumor boost to a dose of 9Gy in 5 fractions (thus total of 54Gy/30Fx to the primary tumor), combined with radio sensitizing chemotherapy. Patients will then be closely monitored, through endoscopy and imaging, for response to treatment and relapse. Salvage oncologic surgery to be offered if there is failure to achieve complete clinical response or in the event of a loco regional relapse.

Trial Details

NCT ID
NCT03001362
Phase
NA
Sponsor
McGill University Health Centre/Research Institute of the McGill University Health Centre
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • Radical external beam radiotherapy
Locations (sample)
  • Montreal, Quebec, Canada|45.50884,-73.58781
  • Montreal, Quebec, Canada|45.50884,-73.58781

Key Eligibility Criteria

  • Pelvic MRI defined disease (at least one of the following):
  • mesorectum involved or breached - includes involvement of adjacent organ (s) (T3-T4)
  • involvement of muscularis propria (T2)
  • extra-mural vascular invasion

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →